Sanofi's Nuvaxovid demonstrates better tolerability compared to mNEXSPIKE

At the ESCMID World Congress in Munich, Sanofi presented data showing that its protein-based vaccine, Nuvaxovid, exhibited better tolerability than Moderna's mRNA vaccine, mNEXSPIKE. In the COMPARE study, 1,000 adults participated in a direct analysis, and the results indicate that systemic and local side effects are significantly less frequent and severe with Nuvaxovid.

Fewer than one in ten people vaccinated with Nuvaxovid reported severe symptoms, compared to one in five for mNEXSPIKE. These results could encourage wider vaccination, addressing concerns about side effects, and promote better annual adherence.